In vitro activity of telithromycin against macrolide-susceptible and macrolide-resistant pharyngeal isolates of group A streptococci in the United States

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 6, 2005, Pages 2487-2489

  Green, Michael ^a   Allen, Coburn ^b   Bradley, John ^c   Dashefsky, Barry ^d   Gilsdorf, Janet R ^e   Marcon, Mario J ^f   Schutze, Gordon E ^g   Smith, Clay ^h   Walter, Emmanuel ⁱ   Martin, Judith M ^a   Edwards, Kathryn A ^h   Barbadora, Karen A ^a   Rumbaugh, Renee M ^a   Wald, Ellen R ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c RADY CHILDREN'S HOSPITAL   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f NATIONWIDE CHILDREN S HOSPITAL   (United States)

^g ARKANSAS CHILDREN S HOSPITAL   (United States)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; LINCOSAMIDE; MACROLIDE; MIKAMYCIN B; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STRAIN DIFFERENCE; STREPTOCOCCUS GROUP A; THROAT CULTURE; UNITED STATES;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; KETOLIDES; MACROLIDES; MICROBIAL SENSITIVITY TESTS; PHARYNX; STREPTOCOCCUS PYOGENES; UNITED STATES;

EID: 21144454230     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.6.2487-2489.2005     Document Type: Article

References (23)

1. Barry, A. L., P. C. Fuchs, and S. D. Brown. 1997. Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA. J. Antimicrob. Chemother. 40:139-140.
2. Cha, S., H. Lee, K. Lee, K. Hwang, S. Bae, and Y. Lee. 2001. The emergence of erythromycin-resistant Streptococcus pyogenes in Seoul, Korea. J. Infect. Chemother. 7:81-86.
3. Coonan, K. M., and E. L. Kaplan. 1994. In vitro susceptibility of recent North American group A streptococcal isolates to eleven oral antibiotics. Pediatr. Infect. Dis. J. 13:630-635.
4. Cornaglia, G., M. Ligozzi, A. Mazzariol, M. Valentini, G. Orefici, R. Fontana, et al. 1996. Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995. Emerg. Infect. Dis. 2:339-342.
5. Farrell, D. J., I. Morrissey, S. Bakker, and D. Felmingham. 2002. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROJEKT 1999-2000 study. J. Antimicrob. Chemother. 50(Suppl. S1):39-47.
6. Freeman, A. F., and S. T. Shulman. 2002. Macrolide resistance in group A streptococcus. Pediatr. Infect. Dis. J. 21:1158-1160.
7. Gerber, M. A. 1995. Antibiotic resistance in group A streptococci. Pediatr. Clin. N. Am. 42:539-551.
8. Hsueh, P. R., L. J. Teng, C. M. Lee, W. K. Huang, T. L. Wu, J. H. Wan, D. Yang, J. M. Shyr, Y. C. Chuang, J. J. Yan, J. J. Lu, J. J. Wu, W. C. Ko, F. Y. Chang, Y. C. Yang, Y. J. Lau, Y. C. Liu, H. S. Leu, C. Y. Liu, K. T. Luh, and the SMART Program. 2003. Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 data. Antimicrob. Agents Chemother. 47:2152-2157.
9. Jacobs, M. R. 2002. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. Clin. Infect. Dis. 35:565-569.
10. Jalava, J., J. Kataja, H. Seppala, and P. Huovinen. 2001. In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species. Antimicrob. Agents Chemother. 45:789-793.
11. Jalava, J., M. Vaara, and P. Huovinen. 2004. Mutation at the position 2058 of the 23S rRNA as a cause of macrolide resistance in Streptococcus pyogenes. Ann. Clin. Microbiol. Antimicrob. 3:5.
12. Kaplan, E. L., D. R. Johnson, M. C. Del Rosario, and D. L. Horn. 1999. Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997. Pediatr. Infect. Dis. J. 18:1069-1072.
13. Kozlov, R. S., T. M. Bogdanovitch, P. C. Appelbaum, L. Ednie, L. S. Stratchounski, M. R. Jacobs, and B. Bozdogan. 2002. Antistreptococcal activity of telithromycin compared with seven other drugs in relation to macrolide resistance mechanisms in Russia. Antimicrob. Agents Chemother. 46:2963-2968.
14. Martin, J. M., M. Green, K. A. Barbadora, and E. R. Wald. 2002. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N. Engl. J. Med. 346:1200-1206.
15. Martin, J. M., E. R. Wald, and M. Green. 1998. Field inversion gel electrophoresis as a typing system for group A streptococcus. J. Infect. Dis. 177:504-507.
16. NCCLS. 2000. Performance standards for susceptibility testing: 10th informational supplement M100-S10 (M7). NCCLS, Wayne, Pa.
17. NCCLS. 2004. Performance standards for antimicrobial susceptibility testing: 14th informational supplement. NCCLS, Wayne, Pa.
18. Schmitz, F. J., S. Schwarz, D. Milatovic, J. Verhoef, and A. C. Fluit. 2002. In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis. J. Antimicrob. Chemother. 50:145-148.
19. Shortridge, V. D., P. Zhong, Z. Cao, J. M. Beyer, L. S. Aimer, N. C. Ramer, S. Z. Doktor, and R. K. Flamm. 2002. Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci. Antimicrob. Agents Chemother. 46:783-786.
20. Sutcliffe, J., A. Tait-Kamradt, and L. Wondrack. 1996. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob. Agents Chemother. 40:1817-1824.
21. Tanz, R. R., S. T. Shulman, V. D. Shortridge, W. Rabat, K. Rabat, E. Cederlund, J. Rippe, J. Beyer, S. Doktor, and B. W. Beall. 2004. Community-based surveillance in the United Stales of macrolide-resistant pediatric pharyngeal group A streptococci during 3 respiratory disease seasons. Clin. Infect. Dis. 39:1794-1801.
22. Ubukata, K., S. Iwata, and K. Sunakawa. 2003. In vitro activities of new ketolide, telithromycin, and eight other macrolide antibiotics against Streptococcus pneumoniae having mefA and ermB genes that mediate macrolide resistance. J. Infect. Chemother. 9:221-226.
23. Weiss, K., J. De Azavedo, C. Restieri, L. A. Galarneau, M. Gourdeau, P. Harvey, J. F. Paradis, K. Salim, and D. E. Low. 2001. Phenotypic and genotypic characterization of macrolide-resistant group A Streptococcus strains in the province of Quebec, Canada. J. Antimicrob. Chemother. 47:345-348.